A new drug to treat Alzheimer’s disease developed by China scientists has been approved by China National Medical Products Administration.
GV-971(Oligomannate), a seaweed-based drug, has been jointly developed by the Ocean University of China, the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Green Valley Pharmaceutical Company Ltd.
According to the scientists they have initiated their researches as noticed that the rate of Alzheimer’s disease occurrence among older people regularly consuming seaweed is relatively low.
In 1997, the study group discovered a unique sugar in algae, which, according to scientists, could play an important role to fight the disease. However, it took more than 20 years to develop this idea and create the drug.
Phase III clinical trial involved about 800 people. The drug demonstrated the ability to improve cognitive function in patients with mild and moderate Alzheimer's disease.
Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. There are about 48 million people worldwide suffer from Alzheimer’s disease.